DOCSLIB.ORG

Supplement, Table 12

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplement, Table 12 Supplement, Table 12. Genes affected by Celecoxib in "cell adhesion" Gene Ontology category Geometri UniGene HUGO Parametric Gene c mean of Cluster ID Symbol p-value ratios P/F Hs.93029 SPOCK sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 0.623 0.00192 Hs.166011 CTNND1 catenin (cadherin-associated protein), delta 1 0.665 0.00006 Hs.334131 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 0.677 0.00280 Hs.423 PAP pancreatitis-associated protein 0.683 0.00400 Hs.85266 ITGB4 integrin, beta 4 0.727 0.02171 Hs.407546 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 0.736 0.00532 Hs.432855 LAMC1 laminin, gamma 1 (formerly LAMB2) 0.751 0.00334 Hs.436593 LMAN1 lectin, mannose-binding, 1 0.754 0.00156 Hs.222 ITGA9 integrin, alpha 9 0.759 0.00809 Hs.8037 TM4SF9 transmembrane 4 superfamily member 9 0.759 0.00146 Hs.25051 PKP2 plakophilin 2 0.774 0.07266 Hs.89436 CDH17 cadherin 17, LI cadherin (liver-intestine) 0.774 0.00173 Hs.48998 FLRT2 fibronectin leucine rich transmembrane protein 2 0.776 0.04264 Hs.173548 NRP1 neuropilin 1 0.784 0.00752 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting Hs.128312 PPFIA1 protein (liprin), alpha 1 0.785 0.00002 Hs.436042 CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 0.788 0.01889 Hs.409546 ARHGAP5 Rho GTPase activating protein 5 0.789 0.01338 Hs.445120 LAMA2 laminin, alpha 2 (merosin, congenital muscular dystrophy) 0.792 0.00052 Hs.436494 JAM2 junctional adhesion molecule 2 0.81 0.01923 Hs.296049 MFAP4 microfibrillar-associated protein 4 0.815 0.00986 Hs.69429 TSC1 tuberous sclerosis 1 0.83 0.00730 Hs.106511 PCDH17 protocadherin 17 0.84 0.00243 Hs.137129 TLN2 talin 2 0.848 0.01058 Hs.77694 MTSS1 metastasis suppressor 1 0.866 0.01002 Hs.441044 EDIL3 EGF-like repeats and discoidin I-like domains 3 1.204 0.01650 Hs.461934 SPN sialophorin (gpL115, leukosialin, CD43) 1.213 0.01122 Hs.288433 HNT neurotrimin 1.215 0.03887 Hs.17893 SCARF1 rab interacting lysosomal protein 1.226 0.00894 Hs.12079 CLSTN2 calsyntenin 2 1.228 0.05976 Hs.415359 DGCR2 DiGeorge syndrome critical region gene 2 1.231 0.03675 Hs.211933 COL13A1 collagen, type XIII, alpha 1 1.233 0.01226 Hs.652 TNFSF5 tumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome) 1.236 0.00908 Hs.439320 ITGA1 integrin, alpha 1 1.25 0.04772 Hs.431010 RELN reelin 1.256 0.00955 Hs.117005 SIGLEC5 sialic acid binding Ig-like lectin 5 1.257 0.07479 Hs.54460 CCL11 chemokine (C-C motif) ligand 11 1.258 0.01054 Hs.79769 PCDH1 protocadherin 1 (cadherin-like 1) 1.263 0.02991 Hs.115418 CDH16 cadherin 16, KSP-cadherin 1.27 0.10631 Hs.79389 NELL2 NEL-like 2 (chicken) 1.271 0.00499 regenerating islet-derived 1 alpha (pancreatic stone protein, pancreatic thread Hs.49407 REG1A protein) 1.273 0.09551 Hs.87149 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 1.291 0.03762 Hs.1416 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23A) 1.299 0.01383 Hs.7019 SIPA1 signal-induced proliferation-associated gene 1 1.299 0.01001 Hs.194657 CDH1 cadherin 1, type 1, E-cadherin (epithelial) 1.31 0.00647 Hs.5302 LGALS4 lectin, galactoside-binding, soluble, 4 (galectin 4) 1.314 0.03158 Hs.54517 FCN2 ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) 1.319 0.09588 Hs.159161 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 1.32 0.00140 Hs.440898 FCN1 ficolin (collagen/fibrinogen domain containing) 1 1.325 0.02024 Hs.85937 MYBPC2 myosin binding protein C, fast type 1.326 0.05897 Hs.408488 MSLN mesothelin 1.33 0.01373 Hs.512682 CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 1.34 0.00954 Hs.153563 LY75 lymphocyte antigen 75 1.354 0.02278 Hs.443518 BPAG1 bullous pemphigoid antigen 1, 230/240kDa 1.355 0.01290 Hs.86947 ADAM8 a disintegrin and metalloproteinase domain 8 1.355 0.00450 Hs.279651 MIA melanoma inhibitory activity 1.357 0.01112 Hs.148090 CDH15 cadherin 15, M-cadherin (myotubule) 1.357 0.04966 collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and Hs.1640 COL7A1 recessive) 1.357 0.00457 Hs.58685 CD5 CD5 antigen (p56-62) 1.385 0.01296 Hs.334846 PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C; nectin) 1.394 0.00332 Hs.1741 ITGB7 integrin, beta 7 1.396 0.00572 Hs.116481 CD72 CD72 antigen 1.418 0.02264 Hs.103707 MUC5AC mucin 5, subtypes A and C, tracheobronchial/gastric 1.448 0.01448 Hs.353214 ICAM3 intercellular adhesion molecule 3 1.457 0.01402 Hs.82848 SELL selectin L (lymphocyte adhesion molecule 1) 1.463 0.05222 Hs.95612 DSC2 desmocollin 2 1.467 0.00168 Hs.387725 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 1.47 0.02576 Hs.194680 WISP1 WNT1 inducible signaling pathway protein 1 1.493 0.00181 Hs.439168 COL11A1 collagen, type XI, alpha 1 1.497 0.02358 Hs.136348 POSTN osteoblast specific factor 2 (fasciclin I-like) 1.521 0.01140 Hs.4817 OPCML opioid binding protein/cell adhesion molecule-like 1.524 0.00782 Hs.116651 EVA1 epithelial V-like antigen 1 1.546 0.00260 Hs.49002 DSCAM Down syndrome cell adhesion molecule 1.739 0.00026 Hs.179729 COL10A1 collagen, type X, alpha 1(Schmid metaphyseal chondrodysplasia) 2.061 0.00004.
Load more

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Comprehensive Molecular Characterization of Gastric Adenocarcinoma
    Comprehensive molecular characterization of gastric adenocarcinoma The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Bass, A. J., V. Thorsson, I. Shmulevich, S. M. Reynolds, M. Miller, B. Bernard, T. Hinoue, et al. 2014. “Comprehensive molecular characterization of gastric adenocarcinoma.” Nature 513 (7517): 202-209. doi:10.1038/nature13480. http://dx.doi.org/10.1038/ nature13480. Published Version doi:10.1038/nature13480 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987344 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA NIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2014 September 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nature. 2014 September 11; 513(7517): 202–209. doi:10.1038/nature13480. Comprehensive molecular characterization of gastric adenocarcinoma A full list of authors and affiliations appears at the end of the article. Abstract Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer
    [Show full text]
  • HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
    Article HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features Lin He 1, Ellen Araj 1 and Yan Peng 1,2,* 1 Department of Pathology, University of Texas Southwestern Medical Center, 6201 Harry Hines Blvd, Dallas, TX 75235, USA; [email protected] (L.H.); [email protected] (E.A.) 2 Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235, USA * Correspondence: [email protected] Abstract: Human epidermal growth factor receptor 2 (HER2) positive (+) classical type invasive lobular carcinoma (cILC) of the breast is extremely rare and its clinicopathologic features have not been well characterized. We compared features of HER2(+) and HER2 negative (−) cILCs. A total of 29 cases were identified from the clinical database at our institution from 2011-2019; 9 were HER2(+) cILC tumors and 20 were HER2(−) cILC tumors. The results reveal that HER2(+) cILC group had significantly increased Ki-67 expression and reduced estrogen receptor (ER) expression compared to HER2(−) cILC group (both p < 0.05). In addition, HER2(+) cILCs tended to be diagnosed at a younger age and more common in the left breast, and appeared to have a higher frequency of nodal or distant metastases. These clinicopathologic features suggest HER2(+) cILC tumors may have more aggressive behavior than their HER2(−) counterpart although both groups of tumors showed similar morphologic features. Future directions of the study: (1) To conduct a multi-institutional study with a larger case series of HER2(+) cILC to further characterize its clinicopathologic features; (2) to compare molecular profiles by next generation sequencing (NGS) assay between HER2(+) cILC and HER2(−) cILC cases to better understand tumor biology of this rare subset of HER2(+) breast cancer; Citation: He, L.; Araj, E.; Peng, Y.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Complement Recognition Pathways in Renal Transplantation
    BRIEF REVIEW www.jasn.org Complement Recognition Pathways in Renal Transplantation Christopher L. Nauser, Conrad A. Farrar, and Steven H. Sacks Medical Research Council Centre for Transplantation, Division of Transplantation Immunology and Mucosal Biology, King’s College London, National Health Service Guy’s and St. Thomas’ Trust, London, United Kingdom ABSTRACT The complement system, consisting of soluble and cell membrane–bound compo- weigh its effect on organ injury and nents of the innate immune system, has defined roles in the pathophysiology of renal rejection with dampening the antimi- allograft rejection. Notably, the unavoidable ischemia-reperfusion injury inherent to crobial functions of the complement sys- transplantation is mediated through the terminal complement activation products tem, such as opsonisation, cell lysis, and C5a and C5b-9. Furthermore, biologically active fragments C3a and C5a, produced recruitment of neutrophils and other in- during complement activation, can modulate both antigen presentation and T cell flammatory cells.7 It is our belief that priming, ultimately leading to allograft rejection. Earlier work identified renal tubule therapeutic strategies can be designed cell synthesis of C3, rather than hepatic synthesis of C3, as the primary source of C3 to specificallytargetthekeyinitiators driving these effects. Recent efforts have focused on identifying the local triggers of of complement activation at the relevant complement activation. Collectin-11, a soluble C-type lectin expressed in renal tis- location, such as complement-binding sue, has been implicated as an important trigger of complement activation in renal anti-HLA antibodies in the vascular tissue. In particular, collectin-11 has been shown to engage L-fucose at sites of compartment or the initiator(s) of local ischemic stress, activating the lectin complement pathway and directing the innate complement activation in the extravas- immune response to the distressed renal tubule.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Prediction of Distant Metastasis by Using Reverse Transcriptase Polymerase Chain Reaction for Epithelial and Variant CD44 Mrna I
    ORIGINAL ARTICLE Prediction of Distant Metastasis by Using Reverse Transcriptase–Polymerase Chain Reaction for Epithelial and Variant CD44 mRNA in the Peripheral Blood of Patients With Colorectal Cancer Shozo Yokoyama, MD; Hiroki Yamaue, MD Background: Reverse transcriptase–polymerase chain Main Outcome Measure: The clinical significance of reaction (RT-PCR) has been used to identify small num- RT-PCR for epithelial and variant CD44 mRNA in pe- bers of tumor cells. Molecular detection is thought to pro- ripheral blood. vide useful information for the clinical management of postoperative adjuvant therapy regimens. Results: During 3 years of follow-up, 2 patients whose peripheral blood had carcinoembryonic antigen and Objective: To use RT-PCR to identify messenger RNA CD44 variant mRNA also had distant metastases (lung (mRNA) coding for carcinoembryonic antigen, epithelial or spleen). Expression of epithelial and variant CD44 and variant CD44, and matrix metalloproteinase 7 in the mRNA in peripheral blood was more highly correlated portal venous and peripheral blood of patients with colo- with the clinical cancer stage than with expression rectal carcinoma to predict live or distant metastasis. of carcinoembryonic antigen and matrix metallopro- teinase 7. Design: Prospective consecutive series. Conclusions: Molecular detection of epithelial and Setting: University hospital. variant CD44 mRNA in the peripheral blood may help determine distant metastases in patients with colorectal Patients and Methods: Portal venous and peripheral carcinoma. Molecular detection in the peripheral blood blood samples were obtained from 22 patients with colo- at surgical treatment suggests that systemic hemato- rectal cancer during surgical manipulation. Using comple- genic tumor cell dissemination is an early event of dis- mentary DNA primers specific for carcinoembryonic tant metastasis.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Human N-Cadherin / CD325 / CDH2 Protein (His & Fc Tag)
    Human N-Cadherin / CD325 / CDH2 Protein (His & Fc Tag) Catalog Number: 11039-H03H General Information SDS-PAGE: Gene Name Synonym: CD325; CDHN; CDw325; NCAD Protein Construction: A DNA sequence encoding the human CDH2 (NP_001783.2) (Met 1-Ala 724) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 70 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method Cadherins are calcium dependent cell adhesion proteins, and they preferentially interact with themselves in a homophilic manner in Stability: connecting cells. Cadherin 2 (CDH2), also known as N-Cadherin (neuronal) (NCAD), is a single-pass tranmembrane protein and a cadherin containing ℃ Samples are stable for up to twelve months from date of receipt at -70 5 cadherin domains. N-Cadherin displays a ubiquitous expression pattern but with different expression levels between endocrine cell types. CDH2 Asp 160 Predicted N terminal: (NCAD) has been shown to play an essential role in normal neuronal Molecular Mass: development, which is implicated in an array of processes including neuronal differentiation and migration, and axon growth and fasciculation. The secreted recombinant human CDH2 is a disulfide-linked homodimeric In addition, N-Cadherin expression was upregulated in human HSC during protein. The reduced monomer comprises 813 amino acids and has a activation in culture, and function or expression blocking of N-Cadherin predicted molecular mass of 89.9 kDa. As a result of glycosylation, it promoted apoptosis. During apoptosis, N-Cadherin was cleaved into 20- migrates as an approximately 114 and 119 kDa band in SDS-PAGE under 100 kDa fragments.
    [Show full text]
  • The N-Cadherin Interactome in Primary Cardiomyocytes As Defined Using Quantitative Proximity Proteomics Yang Li1,*, Chelsea D
    © 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs221606. doi:10.1242/jcs.221606 TOOLS AND RESOURCES The N-cadherin interactome in primary cardiomyocytes as defined using quantitative proximity proteomics Yang Li1,*, Chelsea D. Merkel1,*, Xuemei Zeng2, Jonathon A. Heier1, Pamela S. Cantrell2, Mai Sun2, Donna B. Stolz1, Simon C. Watkins1, Nathan A. Yates1,2,3 and Adam V. Kwiatkowski1,‡ ABSTRACT requires multiple adhesion, cytoskeletal and signaling proteins, The junctional complexes that couple cardiomyocytes must transmit and mutations in these proteins can cause cardiomyopathies (Ehler, the mechanical forces of contraction while maintaining adhesive 2018). However, the molecular composition of ICD junctional homeostasis. The adherens junction (AJ) connects the actomyosin complexes remains poorly defined. – networks of neighboring cardiomyocytes and is required for proper The core of the AJ is the cadherin catenin complex (Halbleib and heart function. Yet little is known about the molecular composition of the Nelson, 2006; Ratheesh and Yap, 2012). Classical cadherins are cardiomyocyte AJ or how it is organized to function under mechanical single-pass transmembrane proteins with an extracellular domain that load. Here, we define the architecture, dynamics and proteome of mediates calcium-dependent homotypic interactions. The adhesive the cardiomyocyte AJ. Mouse neonatal cardiomyocytes assemble properties of classical cadherins are driven by the recruitment of stable AJs along intercellular contacts with organizational and cytosolic catenin proteins to the cadherin tail, with p120-catenin β structural hallmarks similar to mature contacts. We combine (CTNND1) binding to the juxta-membrane domain and -catenin β quantitative mass spectrometry with proximity labeling to identify the (CTNNB1) binding to the distal part of the tail.
    [Show full text]
  • Activation Regulates Alternative Pathway Complement Necrotic
    Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation This information is current as of September 27, 2021. Wei Xu, Stefan P. Berger, Leendert A. Trouw, Hetty C. de Boer, Nicole Schlagwein, Chantal Mutsaers, Mohamed R. Daha and Cees van Kooten J Immunol 2008; 180:7613-7621; ; doi: 10.4049/jimmunol.180.11.7613 Downloaded from http://www.jimmunol.org/content/180/11/7613 References This article cites 56 articles, 27 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/180/11/7613.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation1,2 Wei Xu,* Stefan P. Berger,* Leendert A.
    [Show full text]
  • Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for KN406551 Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product data: Product Type: Knockout Kits (CRISPR) Symbol: Cadherin 16 Locus ID: 1014 Kit Components: , 10 ug , 10 ug : EF1a-GFP-P2A-Puro Disclaimer: The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process. RefSeq: NM_001204744, NM_001204745, NM_001204746, NM_004062 Summary: This gene is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. Mapped to a previously identified cluster of cadherin genes on chromosome 16q22.1, the gene localizes with superfamily members CDH1, CDH3, CDH5, CDH8 and CDH11. The protein consists of an extracellular domain containing 6 cadherin domains, a transmembrane region and a truncated cytoplasmic domain but lacks the prosequence and tripeptide HAV adhesion recognition sequence typical of most classical cadherins. Expression is exclusively in kidney, where the protein functions as the principal mediator of homotypic cellular recognition, playing a role in the morphogenic direction of tissue development. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2020 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) – KN406551 Product images: This product is to be used for laboratory only.
    [Show full text]